Mountain Valley MD Holdings Inc. announced that it has successfully completed its initial safety pre-clinical validation of its solubilized Ivermectin technology.  The trial was conducted to demonstrate the safety and efficacy of the Company's recent invention which enables Ivermectin (among other drugs) to become water-soluble without the use of harmful organic solvents, improving its water solubility by nearly 5,000 times. The pre-clinical canine trial was conducted by a third party preclinical contract research organization ("CRO") and tested the solubilized Ivermectin via both an intramuscular injection and applied to rapid dissolve oral strips with the Company's patented Quicksome™ desiccated liposome technology compared to existing oral and subcutaneous injection solutions.  The results demonstrated a significant improvement in the pharmacokinetic performance of the soluble ivermectin technology with no adverse side effects. MVMD's solubility technology delivered 800% increase in bio availability through intramuscular (IM) injection and 500% increase in bio availability through sublingual strips compared to oral tablets. MVMD's IM injection reaches TMAX (the time to reach the maximum concentration of Ivermectin in the body) at 15 minutes compared to current commercial oral and subcutaneous forms which take between 6 and 36 hours and is well documented.  The Company's sublingual strips had a TMAX of 1 hour, a 600% increase over oral tablets. Both MVMD applications showed zero decline in CMAX (peak serum concentration that a drug achieves) over the entire 6-hour period investigated which the Company considers a very favorable indication over oral and subcutaneous forms. Both MVMD applications show minimal pharmacokinetic variability, with IM injection at zero percent variability and sublingual strips at 5% variability compared to 40% variability for oral tablets.  Variability contributes to the potential for adverse effects or not achieving the required therapeutic index. MVMD's solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity. The Company is proceeding immediately with an extended trial in an effort to document the relative half-life drug data over a longer period of time. As previously reported, MVMD's patent application covers all highly solubilized macrocyclic lactones, including Ivermectin and Selamectin, which have also been shown to be effective in the treatment of tuberculosis even with limited solubility.  The Company believes its solubility technology can dramatically enhance the efficacy of both inhaled and injected Selamectin or Ivermectin providing a novel effective therapeutic for tuberculosis. MVMD notes the testimony of Dr. Pierre Kory, a member of the Front-Line COVID-19 Critical Care Alliance, to the US Homeland Security Committee this week, during which he referenced mounting evidence of the effectiveness of Ivermectin as a therapeutic for COVID-19.  The data Dr. Kory referenced touts the ability of the drug Ivermectin to prevent COVID-19, to keep those with early symptoms from progressing to the hyper-inflammatory phase of the disease, and even to help critically ill patients recover.